Basit öğe kaydını göster

Infectious side effects of baricitinib: A big data analysis based on VigiBase

dc.contributor.authorMahroum, Naim
dc.contributor.authorÖzkan, Mehmet Fatih
dc.contributor.authorAbalı, Tunahan
dc.contributor.authorYılmaz, Mesut
dc.contributor.authorBragazzi, Nicola Luigi
dc.date.accessioned2023-01-06T08:26:40Z
dc.date.available2023-01-06T08:26:40Z
dc.date.issued2023en_US
dc.identifier.citationMahroum, N., Özkan, M. F., Abalı, T., Yılmaz, M. ve Bragazzi, N. L. (2023). Infectious side effects of baricitinib: A big data analysis based on VigiBase. Autoimmunity Reviews, 22(1). https://dx.doi.org/10.1016/j.autrev.2022.103215en_US
dc.identifier.issn1568-9972
dc.identifier.issn1873-0183
dc.identifier.urihttps://dx.doi.org/10.1016/j.autrev.2022.103215
dc.identifier.urihttps://hdl.handle.net/20.500.12511/10255
dc.description.abstractDear Editor, Baricitinib (known as “Olumiant”), is an inhibitor of Janus- associated kinase 1 and 2 (JAK1 and JAK2) initially introduced for the treatment of rheumatoid arthritis (RA), and later for systemic lupus erythematosus (SLE), and atopic dermatitis [1]. The first approval of baricitinib was from the European Medicines Agency (EMA) as a mon- otherapy or combination therapy with methotrexate for patients with RA unresponsive to disease-modifying anti-rheumatic drugs (DMARDs)en_US
dc.language.isoengen_US
dc.publisherElsevier B.V.en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBaricitiniben_US
dc.subjectJAK Inhibitorsen_US
dc.subjectRheumatoid Arthritisen_US
dc.subjectHerpes Zosteren_US
dc.subjectOral Herpesen_US
dc.titleInfectious side effects of baricitinib: A big data analysis based on VigiBaseen_US
dc.typeletteren_US
dc.relation.ispartofAutoimmunity Reviewsen_US
dc.departmentİstanbul Medipol Üniversitesi, Uluslararası Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.authorid0000-0002-7919-1326en_US
dc.authorid0000-0003-1555-4148en_US
dc.authorid0000-0001-5784-726Xen_US
dc.authorid0000-0001-8022-7325en_US
dc.identifier.volume22en_US
dc.identifier.issue1en_US
dc.relation.publicationcategoryDiğeren_US
dc.identifier.doi10.1016/j.autrev.2022.103215en_US
dc.institutionauthorMahroum, Naim
dc.institutionauthorÖzkan, Mehmet Fatih
dc.institutionauthorAbalı, Tunahan
dc.institutionauthorYılmaz, Mesut
dc.identifier.wosqualityQ1en_US
dc.identifier.wos000911106400001en_US
dc.identifier.scopus2-s2.0-85144637273en_US
dc.identifier.pmid36270598en_US
dc.identifier.scopusqualityQ1en_US


Bu öğenin dosyaları:

Thumbnail
Ad:
Mahroum-Naim-2023.pdf
Boyut:
606.1Kb
Biçim:
PDF
Açıklama:
Tam Metin / Full Text
Göster/Aç

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster